So the Holiday Seasons are on, . . . may you break on through (- - -> Easter)

Break on Through (to the other side)
The Doors - Break On Through (To The Other Side) - YouTube

You know the day destroys the night
Night divides the day
Tried to run
Tried to hide
Break on through to the other side
Break on through to the other side
Break on through to the other side, yeah

We chased our pleasures here
Dug our treasures there
But can you still recall
The time we cried?
Break on through to the other side
Break on through to the other side

Yeah
Come on, yeah

Everybody loves my baby
Everybody loves my baby
She get
She get
She get
She get high

I found an island in your arms
Country in your eyes
Arms that chain us
Eyes that lie
Break on through to the other side
Break on through to the other side
Break on through, oww
Oh, yeah

Made the scene
Week to week
Day to day
Hour to hour
The gate is straight
Deep and wide
Break on through to the other side
Break on through to the other side
Break on through
Break on through
Break on through
Break on through
Yeah, yeah, yeah, yeah
Yeah, yeah, yeah, yeah, yeah

Presently, I am contemplating suggesting patients avoid weighing the DiPALS results because the reports are insufficiently detailed for readers to draw conclusions on their own and have many intrinsic conflicts. DiPALS does not contemplate how the variance "Open Label" from the 'traditional' double blind placebo controlled study may have influenced the results at all, much less adequately. Blinding in clinical studies prevents tampering by any entity: the DiPALS "Open Label" approach vastly exposed the research process to external influence and may have produced the results DiPALS regards unhappily. Independent review is constructively disallowed thereby and readers constrained for 'DiPALS word' on the significance of the results. While everyone has a right to their own opinion(s) scientific examination is not provided with such liberty; rather scientific discourse respects the data acquired when offering interpolations thereof weighing hypotheses' validity. In the DiPALS litmus cohort, seven patients prematurely left the study before one year was out; about twenty percent of patients in an ordinary cohort are expected to survive beyond five years (ten percent ten years and five percent twenty years), thus seven or eight patients of a thirty-seven count cohort ought exceed five years . . . instead seven prematurely left (and were thereafter computed as dead even though alive - patients have long expressed disdain for this analytical practice, taken to the extreme here, but previously seen only when patients go for the trach) yet here even before they underwent administration of the medical intervention! The litmus cohort was thus heavily 'front loaded' due the analytical tactic. The control cohort (Noninvasive Ventilation limit) achieved an unprecedented median record high (though no one noticed) - corroborating the plausibility the unidentified internet 'randomization' technique (never previously used in Amyotrophic Lateral Sclerosis) produced biased cohorts { ¿r there e pirates afire }. I can not help but wonder if the DiPALS primary point is the wordlessly stated implication the "Open Label" tactic may be disastrous for clinical studies of Amyotrophic Lateral Sclerosis patients? The DiPALS randomized controlled study achieved 31 moon median in their litmus group but the RespiStimALS randomized controlled study achieved a 56 moon median (nearly par with the Onders's studies) in their litmus group. The "Open Label" status is one of the biggest differences in the two randomized controlled studies. Science benefits more when patients live longer because longer survival correlates with larger quantities of relevant data, the more relevant data we have the sooner we will identify the cause, the sooner we identify the cause(s) the sooner we will find the cure(s). Given the data acquired, the DiPALS really couldn't say much of anything else.

---

Rob Gronkowski, Camille Kostek visit kids at Boston Children's Hospital ahead of Thanksgiving

Rob Gronkowski, Camille Kostek visit kids at Boston Children's Hospital ahead of Thanksgiving

Amyotrophic Lateral Sclerosis patients are kind'a in the same league as Gronk's kids . . .